Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the ...

MIAMI, February 04, 2025--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field ...

Pulse Biosciences (Nasaq:PLSE) announced today that it appointed Jon Skinner as CFO, effective Feb. 3, 2025. Skinner joins the developer of pulsed field ablation (PFA) technology with significant ...

At close: January 17 at 4:00:00 p.m. EST ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (n ...

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA ...

MIAMI - Pulse Biosciences, Inc. (NASDAQ: NASDAQ:PLSE), a bioelectric medicine company focusing on its proprietary CellFX nanosecond Pulsed Field Ablation (nsPFA) technology, has announced the ...